Login Register Cart 0
Research Article

Diagnostic Value of MicroRNA 21 in Endometrial Cancer and Benign Lesions and its Differential Expression with Clinicopathological Parameters

Author(s): Amal Bouziyane, Maryame Lamsisi*, Hicham Benaguida, Mustapha Benhessou, Mohamed El Kerroumi and Moulay Mustapha Ennaji

Volume 10, Issue 2, 2021

Published on: 23 August, 2021

Page: [146 - 152] Pages: 7

DOI: 10.2174/2211536610666210604122816

Price: $65

Abstract

Background: Endometrial cancer is one of the most common malignancies among women worldwide. Although this cancer is often diagnosed at early stages, the need for biomarkers of diagnosis remains a necessity to overcome conventional invasive procedures of diagnosis.

Objective: In our study, we aim to investigate the diagnostic value of microRNA-21 in endometrial cancer and its relation to clinicopathological features.

Methods: We used RT-qPCR to measure the expression of microRNA-21 in 71 tumor tissues, 53 adjacent tissues, and 54 benign lesions.

Results: Our results show that microRNA-21 is a potential biomarker for endometrial cancer with an area under the receiver operating characteristic curve of 0.925 (95% CI = 0.863 - 0.964, P<0.0001). The sensitivity was 84.51% (95% CI = 74.0 - 92.0) and specificity was 86.79% (95% CI = 74.7 - 94.5). For discrimination between benign lesions and controls the AUC was 0,881 with a sensitivity of 100% (95% CI = 93.4 - 100.0) and specificity of 66.04% (95% CI = 51.7 - 78.5), and for discriminating benign lesions from tumors the AUC was 0,750 with a sensitivity of 54.93% (95% CI = 42.7 - 66.8) and specificity of 90.74% (95% CI = 79.7 - 96.9). We also found that tumors with elevated microRNA-21 expression are of advanced FIGO stage, high histological grades, and have cervical invasion, myometrial invasion and distant metastasis.

Conclusion: Our findings support the important role of miR-21 as a biomarker to diagnose endometrial cancer. Further studies on minimally invasive/noninvasive samples such as serum, blood, and urine are necessary to provide a better alternative to current diagnosis methods.

Keywords: Biomarker, clinicopathological features, diagnosis, endometrial cancer, microRNAs, RT-qPCR.

« Previous Next »
Graphical Abstract

[1]
Cancer statistics review. Available at: https://seer.cancer.gov/archive/csr/1975_2014/ [Accessed on: September 22, 2020].
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7-30.
[http://dx.doi.org/10.3322/caac.21332] [PMID: 26742998]
[3]
Sorosky JI. Endometrial cancer. Obstet Gynecol 2012; 120(2): 383-97.
[http://dx.doi.org/10.1097/AOG.0b013e3182605bf1] [PMID: 22825101]
[4]
Rižner TL. Discovery of biomarkers for endometrial cancer: Current status and prospects. Expert Rev Mol Diagn 2016; 16(12): 1315-36.
[http://dx.doi.org/10.1080/14737159.2016.1258302] [PMID: 27817223]
[5]
Kwan JYY, Psarianos P, Bruce JP, Yip KW, Liu FF. The complexity of microRNAs in human cancer. J Radiat Res 2016; 57: i106-11.
[6]
Su Y, Wang J, Ma Z, Gong W, Yu L. MiR-142 suppresses endometrial cancer proliferation in vitro and in vivo by targeting cyclin D1. DNA Cell Biol 2019; 38(2): 144-50.
[http://dx.doi.org/10.1089/dna.2018.4441] [PMID: 30585737]
[7]
Li HL, Sun JJ, Ma H, et al. MicroRNA-23a inhibits endometrial cancer cell development by targeting SIX1. Oncol Lett 2019; 18(4): 3792-802.
[http://dx.doi.org/10.3892/ol.2019.10694] [PMID: 31579409]
[8]
Sun X, Dongol S, Qiu C, et al. MiR-652 promotes tumor proliferation and metastasis by targeting RORA in endometrial cancer. Mol Cancer Res 2018; 16(12): 1927-39.
[http://dx.doi.org/10.1158/1541-7786.MCR-18-0267] [PMID: 30093563]
[9]
Z Z, LJ W, YP X, Y K. MiR-940 potentially promotes proliferation and metastasis of endometrial carcinoma through regulation of MRVI1. Biosci Rep 2019; 39
[http://dx.doi.org/10.1042/BSR20190077]
[10]
Huang YW, Liu JC, Deatherage DE, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009; 69(23): 9038-46.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-1499] [PMID: 19887623]
[11]
Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 2014; 32(1): 41.e1-9.
[http://dx.doi.org/10.1016/j.urolonc.2013.04.011] [PMID: 24035473]
[12]
Zhao Q, Chen S, Zhu Z, et al. MiR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2. Cell Death Dis 2018; 9(12): 1157.
[http://dx.doi.org/10.1038/s41419-018-1182-9] [PMID: 30464258]
[13]
Wang J, Chu Y, Xu M, Zhang X, Zhou Y, Xu M. MiR-21 promotes cell migration and invasion of hepatocellular carcinoma by targeting KLF5. Oncol Lett 2019; 17(2): 2221-7.
[http://dx.doi.org/10.3892/ol.2018.9843] [PMID: 30675287]
[14]
Qiu Y-F, Wang M-X, Meng L-N, Zhang R, Wang W. MiR-21 regulates proliferation and apoptosis of oral cancer cells through TNF-α. Eur Rev Med Pharmacol Sci 2018; 22(22): 77325-41.
[http://dx.doi.org/10.26355/EURREV_201811_16395]
[15]
Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A, et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther Nucleic Acids 2020; 20: 409-20.
[http://dx.doi.org/10.1016/j.omtn.2020.03.003] [PMID: 32244168]
[16]
Zhao W, Geng P, Li Y, Wei X, Cheng J. MicroRNA-21 promotes endometrial carcinoma proliferation and invasion by targeting PTEN. Int J Clin Exp Pathol 2017; 10(12): 11489-95.
[PMID: 31966504]
[17]
Qin X, Yan L, Zhao X, Li C, Fu Y. microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer. Oncol Lett 2012; 4(6): 1290-6.
[http://dx.doi.org/10.3892/ol.2012.896] [PMID: 23226804]
[18]
Lee H, Choi HJ, Kang CS, Lee HJ, Lee WS, Park CS. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Mod Pathol 2012; 25(11): 1508-15.
[http://dx.doi.org/10.1038/modpathol.2012.111] [PMID: 22766795]
[19]
Torres A, Torres K, Paszkowski T, et al. Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer: A preliminary report. Int J Gynecol Cancer 2011; 21(1): 8-14.
[http://dx.doi.org/10.1097/IGC.0b013e318200050e] [PMID: 21330826]
[20]
Gao Y, Dai M, Liu H, et al. Diagnostic value of circulating miR-21: An update meta-analysis in various cancers and validation in endometrial cancer. Oncotarget 2016; 7(42): 68894-908.
[http://dx.doi.org/10.18632/oncotarget.12028] [PMID: 27655698]
[21]
Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14(11): 2348-60.
[http://dx.doi.org/10.1261/rna.1034808] [PMID: 18812439]
[22]
Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013; 105(12): 849-59.
[http://dx.doi.org/10.1093/jnci/djt101] [PMID: 23704278]
[23]
Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010; 64(6): 399-408.
[http://dx.doi.org/10.1016/j.biopha.2010.01.018] [PMID: 20363096]
[24]
Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res 2013; 25(6): 743-8.
[http://dx.doi.org/10.3978/j.issn.1000-9604.2013.12.04] [PMID: 24385703]
[25]
Li S, Yang X, Yang J, Zhen J, Zhang D. Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: A systematic review and meta-analysis. Clin Exp Med 2016; 16(1): 29-35.
[http://dx.doi.org/10.1007/s10238-014-0332-3] [PMID: 25516467]
[26]
Shan L, Ji Q, Cheng G, et al. Diagnostic value of circulating miR-21 for colorectal cancer: A meta-analysis. Cancer Biomark 2015; 15(1): 47-56.
[http://dx.doi.org/10.3233/CBM-140437] [PMID: 25524942]
[27]
Wu R, Jiang Y, Wu Q, et al. Diagnostic value of microRNA-21 in the diagnosis of lung cancer: Evidence from a meta-analysis involving 11 studies. Tumour Biol 2014; 35(9): 8829-36.
[http://dx.doi.org/10.1007/s13277-014-2106-7] [PMID: 24880588]
[28]
Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79(3-4): 313-20.
[http://dx.doi.org/10.1159/000323283] [PMID: 21412018]
[29]
Huang GL, Zhang XH, Guo GL, et al. Clinical significance of miR-21 expression in breast cancer: SYBR-green I-based real- time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009; 21(3): 673-9.
[http://dx.doi.org/10.3892/or_00000270] [PMID: 19212625]
[30]
Zmarzły N, Hermyt E, Witek A, Gola J, Mazurek U. Liquid biopsy in endometrial cancer. Curr Gynecol Oncol 2019; 17: 27-42.
[http://dx.doi.org/10.15557/CGO.2019.0004]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy